Format

Send to

Choose Destination
Breast Cancer Res Treat. 1994 Jan;29(1):117-25.

Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy.

Author information

1
Tenovus Cancer Research Centre, University of Wales College of Medicine, The Heath, Cardiff, U.K.

Abstract

106 previously untreated breast cancer patients have been immunohistochemically analysed for EGF-R, ER, Ki67, and c-erbB-2 product. All patients received assessable endocrine therapy following disease progression. Significant associations were observed between EGF-R and ER (inverse) and Ki67 (direct). No association was observed between EGF-R and the c-erbB-2 product. EGF-R expression was significantly associated with the loss of endocrine sensitivity in breast cancer. This was observed in both ER positive and negative disease. In ER positive breast cancers, EGF-R expression had no significant influence on the quality of tumour remissions. Further sub-classification of the ER/EGF-R data by Ki67 immunostaining showed that in ER+/EGF-R-disease, increasing proportions of Ki67 positive cells were associated with a decline in the numbers of women experiencing good quality tumour remissions. A similar trend was also observed in ER+/EGF-R+ tumours. The presence of c-erbB-2 protein product did not influence endocrine sensitivity in any of the ER/EGF-R sub-groups.

PMID:
7912565
DOI:
10.1007/bf00666187
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center